Theraclion

Theraclion Interest Coverage

The Interest Coverage Ratio of Theraclion (ALTHE.PA) as of Nov 4, 2026 is -52.10. In the previous year, Interest Coverage Ratio was -40.64 — a change of 28.17% (lower).

Interest Coverage

-52.10

YoY

28.17%

Last updated:

Interest Coverage Ratio of Theraclion is 2024 -52.10 . Interest Coverage Ratio of Theraclion was 2023 -40.64 . It decreases by 28.17% lower compared to the previous year.

The Theraclion Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-27.88 EUR
Jan 1, 2018
-25.75 EUR
Jan 1, 2019
-20.90 EUR
Jan 1, 2020
-15.76 EUR
Jan 1, 2021
-28.30 EUR
Jan 1, 2022
-307.68 EUR
Jan 1, 2023
-40.64 EUR
Jan 1, 2024
-52.10 EUR
The Theraclion Interest Coverage history
YEARInterest CoverageYoY
-52.10+28.17%
-40.64-86.79%
-307.68+987.30%
-28.30+79.56%
-15.76-24.58%
-20.90-18.84%
-25.75-7.64%
-27.88-14.75%
-32.70-33.21%
-48.96+80.96%
-27.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Theraclion Stock analysis

What does Theraclion do? Theraclion SA is a French medical company specializing in the development and production of innovative therapy systems. The company was founded in 2004 and is headquartered in Malakoff, France. Theraclion's business model is based on the development and marketing of medical devices based on High Intensity Focused Ultrasound (HIFU) technology. This technology uses ultrasound pulses to treat targeted areas in the body without the need for surgical intervention. Theraclion specializes in three main areas: oncology, dermatology, and aesthetics. In the field of oncology, Theraclion has developed the Echopulse system, which is used for the treatment of breast tumors. The system applies high-intensity ultrasound pulses to kill tumor cells without damaging surrounding tissue. This non-invasive method of tumor treatment is very promising and has already shown promising results in several studies. In the field of dermatology, Theraclion has developed the Echovist system, which is used for the treatment of nevi (moles). The system also utilizes HIFU technology to destroy the nevi, resulting in a significant improvement in the aesthetic appearance of the skin. In the field of aesthetics, Theraclion has developed the Sonovein system, which is used for the treatment of varicose veins. The system also utilizes HIFU technology to close the veins and thus improve the patient's appearance and quality of life. Theraclion has experienced impressive growth in recent years and is now an important player in the medical industry. The company has filed several patents and works closely with leading doctors and research institutions to maximize the effectiveness of its products. Overall, Theraclion aims to offer innovative therapies that meet the needs of patients and help them lead fulfilling lives. The company is committed to continuously improving its products and services and strives to achieve even greater successes in the future. Theraclion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Theraclion stock

Interest Coverage Ratio of Theraclion is -52.10 in 2024.

Interest Coverage Ratio of Theraclion changed from -40.64 to -52.10, representing a 28.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Theraclion since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Theraclion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Theraclion

All Key Metrics — Theraclion